sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_5419> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_5419> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB04946> ;
    a rdf:Statement ;
    rdfs:label "fanapt r see clinical studies 14 when deciding among the alternative treatments available for this condition the prescriber should consider the finding that fanapt see warnings and precaution s 5 2 patients must be titrated to an effective dose of fanapt s ee dosage and administration 2 1 and clinical studies 14 the effectiveness of fanapt in long term use that is for more than 6 weeks has not been systematically evaluated in controlled trials therefore the physician who elects to use fanapt for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient s ee dosage and administration 2 3 fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults 1 14" ;
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation schema:TreatmentIndication .
  <https://identifiers.org/drugbank:DB04946> bl:category bl:Drug .
}